Exudative Age‑Related Macular Degeneration - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Exudative Age‑Related Macular Degeneration – Complete Guide

Exudative Age‑Related Macular Degeneration (AMD)

Overview

Exudative age‑related macular degeneration (also called “wet” AMD) is a progressive eye disease that damages the macula—the central part of the retina responsible for sharp, straight‑ahead vision. In the exudative form, abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid vision loss.

  • Who it affects: Primarily adults 60 years or older; the risk rises sharply after age 70.
  • Prevalence: In the United States, ~1.75 million people have wet AMD, representing about 10–15 % of all AMD cases, but it accounts for roughly 90 % of AMD‑related severe vision loss.[1][2]
  • Geographic variation: Higher prevalence in Caucasian populations; lower in Asian and African‑descent groups, though rates are rising worldwide as populations age.[3]

Symptoms

Symptoms can develop suddenly or over weeks. Early detection is crucial because treatment can preserve vision.

  • Metamorphopsia (distorted vision): Straight lines appear wavy or bent.
  • Central visual blur: Loss of fine detail in the center of the visual field.
  • Dark or empty spot in the center of vision: A scotoma that may expand over time.
  • Decreased ability to see colors: Colors may look faded.
  • Difficulty reading or recognizing faces: Tasks that require fine central vision become challenging.
  • Rapid change in vision: Unlike dry AMD, which progresses slowly, wet AMD can cause noticeable deterioration within days to weeks.
  • Floaters or flashes (less common): When bleeding occurs under the retina.

Causes and Risk Factors

Underlying Pathophysiology

Wet AMD results from choroidal neovascularization (CNV). Damage to retinal pigment epithelium (RPE) and Bruch’s membrane triggers the release of vascular endothelial growth factor (VEGF), stimulating new, fragile blood vessels that leak fluid, lipids, and blood into the sub‑retinal space.

Major Risk Factors

  • Age: Risk doubles every decade after 60.
  • Genetics: Variants in CFH, ARMS2/HTRA1 genes increase susceptibility.[4]
  • Smoking: Current smokers have a 2–3‑fold higher risk.[5]
  • Race/Ethnicity: Caucasians > African‑Americans > Asians.
  • Family history: First‑degree relatives with AMD raise risk markedly.
  • Cardiovascular disease & hypertension: Shared vascular pathways.
  • Obesity & high‑cholesterol diet: Contribute to inflammatory milieu.
  • Excessive sunlight exposure: Cumulative UV‑blue light may accelerate retinal damage.
  • Gender: Slightly higher incidence in women, possibly reflecting longevity.

Diagnosis

Diagnosing wet AMD requires a combination of patient history, visual testing, and imaging.

Clinical Examination

  • Amsler grid testing: Simple home tool to detect metamorphopsia.
  • Visual acuity test: Measures central vision clarity.

Imaging Modalities

  • Optical Coherence Tomography (OCT): High‑resolution cross‑sectional images reveal fluid, thickening, and neovascular membranes.
  • Fluorescein Angiography (FA): Dye injected intravenously highlights leaking vessels.
  • Indocyanine Green Angiography (ICGA): Better for detecting polypoidal choroidal vasculopathy, a variant of wet AMD.
  • Fundus Photography: Baseline documentation for monitoring progression.

Laboratory Work‑up

Generally not required for diagnosis, but blood work (lipid profile, HbA1c) may be ordered to address modifiable cardiovascular risk factors.

Treatment Options

Timely therapy can halt leakage, shrink abnormal vessels, and often improve vision.

Pharmacologic (Anti‑VEGF) Therapy

  • Aflibercept (Eylea): Binds VEGF‑A, VEGF‑B, and PlGF; given every 4–8 weeks after loading phase.
  • Ranibizumab (Lucentis): FDA‑approved for AMD; typically monthly injections, may extend to 12‑week intervals with “treat‑and‑extend” protocols.
  • Bevacizumab (Avastin): Off‑label but cost‑effective; similar efficacy in many studies.
  • Faricimab (Vabysmo): Dual‑target (VEGF‑A & Ang‑2) – allows up to 16‑week dosing in select patients (approved 2022).

Most patients require an initial series of three monthly injections (loading phase) followed by individualized maintenance.

Photodynamic Therapy (PDT)

Used less frequently now, PDT with verteporfin is helpful for polypoidal lesions or when anti‑VEGF alone is insufficient.

Laser Photocoagulation

Direct laser destroys leaking vessels but also damages overlying retina; reserved for extrafoveal lesions where sight loss would be minimal.

Surgical Options

  • Sub‑macular surgery: Removal of fibrotic scar tissue; limited to select cases.
  • Vitrectomy with membrane peel: Considered for severe tractional components.

Adjunct Lifestyle & Nutritional Interventions

  • AREDS2 supplement regimen: 500 mg vitamin C, 400 IU vitamin E, 80 mg zinc, 2 mg copper, plus 10 mg lutein + 2 mg zeaxanthin daily. Shown to reduce progression of intermediate AMD to advanced forms by ~25 %.[6]
  • Smoking cessation, blood pressure control, lipid management: Improves overall vascular health.

Living with Exudative Age‑Related Macular Degeneration

Vision‑Enhancement Strategies

  • Low‑vision aids: High‑contrast reading glasses, magnifiers, electronic screen readers.
  • Lighting: Bright, evenly distributed lighting reduces glare and improves contrast.
  • Adaptive technology: Smartphone apps (e.g., “Magnifying Glass + Flash”), screen‑reader software, and voice‑controlled assistants.

Daily Activity Adjustments

  • Prefer large‑print books, audio books, and podcasts.
  • Organize home items consistently; use tactile labels.
  • When driving, consider a professional assessment; many states require a vision test after diagnosis.

Emotional & Social Support

Vision loss can lead to anxiety and depression. Encourage:

  • Joining local or online support groups (e.g., Macular Degeneration Association).
  • Counseling or vision‑rehabilitation services.
  • Regular eye‑care follow‑up to maintain hope and monitor treatment response.

Prevention

While age cannot be changed, several modifiable factors lower the risk of developing wet AMD or slowing its progression.

  • Nutrition: Eat a diet rich in leafy greens (spinach, kale), colorful fruits, fish high in omega‑3 fatty acids, and nuts.
  • Quit smoking: Benefits appear within 1–2 years of cessation.
  • Maintain healthy blood pressure and cholesterol: Follow the DASH or Mediterranean diet.
  • Protect eyes from UV/blue light: Wear sunglasses with 99–100 % UV protection and consider blue‑light‑filtering lenses when using digital devices.
  • Regular eye examinations: Adults ≥ 50 years should have a dilated exam every 1–2 years; those with early AMD may need yearly monitoring.
  • Supplementation: For those with intermediate AMD, the AREDS2 formulation is recommended after consulting an eye‑care professional.

Complications

If untreated or inadequately managed, wet AMD can lead to:

  • Permanent central vision loss: Inability to read, recognize faces, or perform fine motor tasks.
  • Geographic atrophy: Degeneration of surrounding retinal tissue after chronic CNV activity.
  • Fibrotic scar formation (disciform scar): Irreversible scarring that replaces macular tissue.
  • Legal blindness: Defined as visual acuity worse than 20/200 in the better‑seeing eye.
  • Increased risk of falls and accidents: Due to reduced depth perception and central vision.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice:
  • Sudden, severe loss of vision in one eye.
  • Rapid increase in the size of a dark spot or “hole” in the center of vision.
  • Sudden appearance of many floaters, flashes of light, or a curtain‑like shadow across the visual field.
  • Acute eye pain, redness, or swelling together with vision changes (could indicate an associated ocular infection or hemorrhage).
Prompt evaluation can prevent irreversible damage.

References

  1. Mayo Clinic. “Age-related macular degeneration (dry and wet).” Updated 2023.
  2. National Eye Institute. “Facts About Age-Related Macular Degeneration.” 2022.
  3. World Health Organization. “Global prevalence of age‑related macular degeneration.” 2021.
  4. U.S. National Library of Medicine, PMID: 31023323 – Genetic risk factors for AMD.
  5. CDC. “Smoking and Age‑Related Macular Degeneration.” 2020.
  6. Age‑Related Eye Disease Study 2 Research Group. “Lutein + Zeaxanthin and Visual Function in AMD.” JAMA Ophthalmology, 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References